We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

126 hedge funds and large institutions have $591M invested in Momenta Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 54 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

123% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 13

100% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 27

55% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $8.7M

14% more funds holding

Funds holding: 111126 (+15)

7% less capital invested

Capital invested by funds: $635M → $591M (-$43.5M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
126
Holders Change
+15
Holders Change %
+13.51%
% of All Funds
4.09%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
29
Increased
54
Reduced
27
Closed
13
Calls
$13.5M
Puts
$8.7M
Net Calls
+$4.76M
Net Calls Change
-$1.07M
Name Holding Trade Value Shares
Change
Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$5.03M +$1.11M +72,304 +26%
AQR Capital Management
27
AQR Capital Management
Connecticut
$4.37M -$3.25M -212,284 -41%
IGIM
28
I.G. Investment Management
Manitoba, Canada
$4.35M +$4.62M +302,000 New
TCIM
29
TIAA CREF Investment Management
New York
$3.97M -$88.6K -5,787 -2%
Principal Financial Group
30
Principal Financial Group
Iowa
$3.9M +$452K +29,537 +12%
WC
31
Wexford Capital
Florida
$3.64M +$3.1M +202,500 +401%
AC
32
Ascend Capital
California
$3.51M +$2.22M +145,137 +147%
BNP Paribas Asset Management
33
BNP Paribas Asset Management
France
$3.26M +$3.47M +226,471 New
Geode Capital Management
34
Geode Capital Management
Massachusetts
$3.14M +$456K +29,763 +16%
CS
35
Credit Suisse
Switzerland
$3.13M +$1.95M +127,446 +142%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$2.98M -$1.13M -73,800 -26%
Charles Schwab
37
Charles Schwab
California
$2.98M +$1.34M +87,846 +80%
Citadel Advisors
38
Citadel Advisors
Florida
$2.78M -$11.7M -765,620 -80%
BG
39
BlackRock Group
United Kingdom
$2.74M +$378K +24,681 +15%
U
40
UBS
Switzerland
$2.73M +$2.64M +172,298 +993%
SGA
41
Sector Gamma AS
Norway
$2.69M +$334K +21,800 +13%
Ameriprise
42
Ameriprise
Minnesota
$2.53M +$95.3K +6,230 +4%
PP
43
PDT Partners
New York
$2.5M -$84K -5,489 -3%
Deutsche Bank
44
Deutsche Bank
Germany
$2.48M +$426K +27,836 +19%
BIM
45
BlackRock Investment Management
Delaware
$2.34M +$105K +6,847 +4%
CII
46
CR Intrinsic Investors
Connecticut
$2.3M -$1.38M -90,000 -36%
Morgan Stanley
47
Morgan Stanley
New York
$2.08M +$1.77M +115,713 +399%
Invesco
48
Invesco
Georgia
$2.05M +$308K +20,146 +16%
WHI
49
William Harris Investors
Illinois
$2.02M +$2.14M +140,000 New
California Public Employees Retirement System
50
California Public Employees Retirement System
California
$1.72M +$274K +17,900 +18%

MNTA Hedge Fund Activity: Q3 2013 in Review

126 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2013, worth a combined $591M — down 6.9% from $635M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new MNTA positions and 13 closed out — a net gain of 16 holders — while 54 added to existing stakes and 27 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $30.7M. The largest seller was Visium Asset Management, cutting an estimated $65M.

  • 126 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2013, up from 111 in Q2 2013.
  • Funds reported $591M of Momenta Pharmaceuticals, Inc. stock for Q3 2013, down 6.9% quarter-over-quarter.
  • 29 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2013 and 13 closed out, a net change of +16 holders.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2013 was Deerfield Management, an estimated $30.7M added.
  • The largest Momenta Pharmaceuticals, Inc. seller in Q3 2013 was Visium Asset Management, an estimated $65M sold.

Based on aggregated 13F filings for Q3 2013.